Stocks and Investing Stocks and Investing
Tue, April 5, 2022
Mon, April 4, 2022
Sun, April 3, 2022
Fri, April 1, 2022
Thu, March 31, 2022

Evan Seigerman Maintained (CADL) at Buy with Decreased Target to $12 on, Mar 31st, 2022


Published on 2024-10-27 20:15:23 - WOPRAI
  Print publication without navigation


Evan Seigerman of BMO Capital, Maintained "Candel Therapeutics, Inc." (CADL) at Buy with Decreased Target from $18 to $12 on, Mar 31st, 2022.

Evan, nor any peers, have made any analyst calls on CADL in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30